Concepts of ‘Personalization’ in Personalized Medicine: Implications for Economic Evaluation
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Concepts of ‘Personalization’ in Personalized Medicine: Implications for Economic Evaluation
Authors
Keywords
Economic Evaluation, Lynch Syndrome, Health Technology Assessment, Personalize Medicine, Health State Valuation
Journal
PHARMACOECONOMICS
Volume 33, Issue 1, Pages 49-59
Publisher
Springer Nature
Online
2014-09-24
DOI
10.1007/s40273-014-0211-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer
- (2014) Florian Koerber et al. BMC HEALTH SERVICES RESEARCH
- Personalized Genomic Medicine and the Rhetoric of Empowerment
- (2014) Eric T. Juengst et al. HASTINGS CENTER REPORT
- The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis
- (2014) W Rogowski et al. HEALTH TECHNOLOGY ASSESSMENT
- The Value of Heterogeneity for Cost-Effectiveness Subgroup Analysis
- (2014) Manuel A. Espinoza et al. MEDICAL DECISION MAKING
- Is Individualized Medicine More Cost-Effective? A Systematic Review
- (2014) Maximilian H. M. Hatz et al. PHARMACOECONOMICS
- The Behavioral Economics of Health and Health Care
- (2013) Thomas Rice Annual Review of Public Health
- What is personalized medicine: sharpening a vague term based on a systematic literature review
- (2013) Sebastian Schleidgen et al. BMC Medical Ethics
- The economic value of personalized medicine tests: what we know and what we need to know
- (2013) Kathryn A Phillips et al. GENETICS IN MEDICINE
- HETEROGENEITY IN ACTION: THE ROLE OFPASSIVEPERSONALIZATION IN COMPARATIVE EFFECTIVENESS RESEARCH
- (2013) Anirban Basu et al. HEALTH ECONOMICS
- Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis
- (2013) Katharina E. Fischer et al. HEALTH POLICY
- The Optimal Practice of Evidence-Based Medicine
- (2013) Victor M. Montori et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Review of the Cost Effectiveness of Pharmacogenetic-Guided Treatment of Hypercholesterolaemia
- (2013) Michael J. Sorich et al. PHARMACOECONOMICS
- Methods to Elicit Probability Distributions from Experts: A Systematic Review of Reported Practice in Health Technology Assessment
- (2013) Bogdan Grigore et al. PHARMACOECONOMICS
- Current Methodological Issues in the Economic Assessment of Personalized Medicine
- (2013) Lieven Annemans et al. VALUE IN HEALTH
- Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force
- (2013) F. Reed Johnson et al. VALUE IN HEALTH
- Patient empowerment: The need to consider it as a measurable patient-reported outcome for chronic conditions
- (2012) Marion McAllister et al. BMC HEALTH SERVICES RESEARCH
- Die Nutzung von Informationswertanalysen in Entscheidungen über angewandte Forschung
- (2012) W.H. Rogowski et al. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz
- VALUING THE ECONOMIC BENEFITS OF COMPLEX INTERVENTIONS: WHEN MAXIMISING HEALTH IS NOT SUFFICIENT
- (2012) Katherine Payne et al. HEALTH ECONOMICS
- Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group
- (2012) Eric Faulkner et al. VALUE IN HEALTH
- State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3
- (2012) Uwe Siebert et al. VALUE IN HEALTH
- Modeling using Discrete Event Simulation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4
- (2012) Jonathan Karnon et al. VALUE IN HEALTH
- A review of economic evaluations of genetic testing services and interventions (2004–2009)
- (2011) Sandjar Djalalov et al. GENETICS IN MEDICINE
- Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care
- (2011) Anirban Basu JOURNAL OF HEALTH ECONOMICS
- Subgroup analyses of clinical effectiveness to support health technology assessments
- (2011) Marie-Ange Paget et al. PHARMACEUTICAL STATISTICS
- The Economic Burden of Incidentally Detected Findings
- (2011) Alexander Ding et al. RADIOLOGIC CLINICS OF NORTH AMERICA
- Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force
- (2011) John F.P. Bridges et al. VALUE IN HEALTH
- The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer
- (2010) Mercy Mvundura et al. GENETICS IN MEDICINE
- Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents
- (2010) Peter J. Neumann et al. HEALTH ECONOMICS
- Cost Effectiveness of Pharmacogenomics
- (2010) William B. Wong et al. PHARMACOECONOMICS
- Quantifying Women's Stated Benefit–Risk Trade-Off Preferences for IBS Treatment Outcomes
- (2010) F. Reed Johnson et al. VALUE IN HEALTH
- Colon cancer screening practices and disclosure after receipt of positive or inconclusive genetic test results for hereditary nonpolyposis colorectal cancer
- (2009) Anne L. Ersig et al. CANCER
- Challenges of translating genetic tests into clinical and public health practice
- (2009) Wolf H. Rogowski et al. NATURE REVIEWS GENETICS
- Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes
- (2009) Stefan Vegter et al. PHARMACOECONOMICS
- Good Research Practices for Comparative Effectiveness Research: Analytic Methods to Improve Causal Inference from Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part III
- (2009) Michael L. Johnson et al. VALUE IN HEALTH
- Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis
- (2008) Scott D Grosse et al. GENETICS IN MEDICINE
- The Half-Life of Truth: What Are Appropriate Time Horizons for Research Decisions?
- (2008) Zoe Philips et al. MEDICAL DECISION MAKING
- Understanding Medication Compliance and Persistence from an Economics Perspective
- (2008) Rachel A. Elliott et al. VALUE IN HEALTH
- Welfarism vs. extra-welfarism
- (2007) Werner B.F. Brouwer et al. JOURNAL OF HEALTH ECONOMICS
- Modelling heterogeneity in patients’ preferences for the attributes of a general practitioner appointment
- (2007) Arne Risa Hole JOURNAL OF HEALTH ECONOMICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now